Next Article in Journal
B0 Correction for 3T Amide Proton Transfer (APT) MRI Using a Simplified Two-Pool Lorentzian Model of Symmetric Water and Asymmetric Solutes
Previous Article in Journal
Partial Anomalous Left Pulmonary Artery Anterior Versus Posterior Types: A Systematic Review

Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies

Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA
School of Science and Technology, The University of Georgia, Tbilisi 0171, Georgia
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tabriz 5166, Iran
Taba Medical Imaging Center, Shiraz 71347-53151, Iran
Department of Diagnostic & Interventional Radiology, New Hospitals Ltd., Tbilisi 0114, Georgia
Author to whom correspondence should be addressed.
Academic Editor: Emilio Quaia
Tomography 2022, 8(4), 1959-1973;
Received: 2 June 2022 / Revised: 19 July 2022 / Accepted: 25 July 2022 / Published: 30 July 2022
(This article belongs to the Section Cardiovascular Imaging)
We reviewed the reported imaging findings of myocarditis in the literature following COVID-19 vaccination on cardiac imaging by a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), and Google Scholar. In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). The distribution of patients receiving vaccine dosage was investigated. On cardiac MR Imaging, late intravenous gadolinium enhancement (LGE) was observed mainly in the epicardial/subepicardial segments (90.8%, 318 of 350 enhancing segments), with the dominance of inferolateral segment and inferior walls. Pericardial effusion was reported in 13.1% of cases. The vast majority of patients (94%, 500 of 532) were discharged from the hospital except for 4 (0.7%) cases. Post-COVID-19 myocarditis was most commonly reported in symptomatic men after the second or third dose, with CMRI findings including LGE in 90.8% of inferior and inferolateral epicardial/subepicardial segments. Most cases were self-limited. View Full-Text
Keywords: coronavirus; myocarditis; Pfizer-BioNTech; Moderna; Janssen/Johnson & Johnson coronavirus; myocarditis; Pfizer-BioNTech; Moderna; Janssen/Johnson & Johnson
Show Figures

Figure 1

MDPI and ACS Style

Keshavarz, P.; Yazdanpanah, F.; Emad, M.; Hajati, A.; Nejati, S.F.; Ebrahimian Sadabad, F.; Azrumelashvili, T.; Mizandari, M.; Raman, S.S. Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies. Tomography 2022, 8, 1959-1973.

AMA Style

Keshavarz P, Yazdanpanah F, Emad M, Hajati A, Nejati SF, Ebrahimian Sadabad F, Azrumelashvili T, Mizandari M, Raman SS. Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies. Tomography. 2022; 8(4):1959-1973.

Chicago/Turabian Style

Keshavarz, Pedram, Fereshteh Yazdanpanah, Maryam Emad, Azadeh Hajati, Seyed Faraz Nejati, Faranak Ebrahimian Sadabad, Tamta Azrumelashvili, Malkhaz Mizandari, and Steven S. Raman. 2022. "Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies" Tomography 8, no. 4: 1959-1973.

Find Other Styles

Article Access Map by Country/Region

Back to TopTop